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Abstract
Pantothenate Kinase-Associated
Neurodegeneration (PKAN) is an autoso-
mal recessive disorder characterized by a
mutation in the PANK2 gene. The clinical
presentation may range from only speech
disorder to severe generalized dystonia,
spasticity, Visual loss, dysphagia and
dementia. The hallmark of this disease is
eyes of the tiger sign in the medial aspect of
bilateral globus pallidus on T2-weighted
MRI that is a hyperintense lesion surround-
ed by hypointensity. Common treatments
for PKAN disease include anticholinergics,
botulinum toxin, Oral and Intrathecal
baclofen, Iron chelation drugs and surgical
procedures such as ablative pallidotomy or
thalamotomy, Deep brain stimulation.
There are many controversies about the
pathogenesis and treatment of this disease,
and in recent years interesting studies have
been done on PKAN disease and other sim-
ilar diseases. This review summarizes the
clinical presentation, etiology, imaging
modalities and treatment. 
Introduction
Neurodegeneration with brain iron
accumulation (NBIA) is a wide number of
neurodegenerative disorders characterized
by iron accumulation in the brain, especial-
ly basal ganglia, substantia nigari, hip-
pocampus and cerebellar nuclei.1,2 The typ-
ical presentation of NBIA disorder includes
dystonia, Parkinsonism, choreoathetosis,
mental dysfunction, spasticity, visual distur-
bance and bulbar dysfunction.3 The most
common form of NBIA is PKAN also
known as NBIA-1 that is an autosomal
recessive disorder characterized by a muta-
tion in the PANK 2 at locus 20 P12.3 This
disease also has various psychiatry symp-
toms.4-6 This review aims to describe the
clinical manifestation, pathophysiology and
the treatment of PKAN disease.
Materials and Methods
Etiology
The iron normally accumulated in the
basal ganglia, hippocampus, cerebellar
nuclei and another subcortical region.7 The
PKAN characterized by a mutation in the
PANK 2 that codes the pantothenate kinase
2. Mutations are missense, duplication,
deletion, splice site mutation and deletion of
exon.8 This protein kinase is responsible for
the phosphorylation of pantothenate and
this product combine with cysteine. The
cysteine increase in the globus pallidus of
patients with PKAN that in association with
iron produce free radicals and cell dama-
ge.9,10 The Mutations of PANK2 also found
in patients with HARP (hypoprebetalipo-
proteinemia, acanthocytosis, retinitis pig-
mentosa, and pallidal degeneration). The
HARP is rare disease and has mental decli-
ne, abnormal movement and vision loss.11
Diagnosis
Today, the PKAN disease is diagnosed
by magnetic resonance imaging and con-
firmed with the genetic test.12 Susceptibility
weighted imaging (SWI) and field dependent
R2 increase (FDRI) are the choice methods
for the diagnosis of this disease and FDRI is
more sensitive than SWI for detection of
brain iron.13 We can also use the cranial
sonography that detects the over load of iron
in midbrain.14 The hallmark of this disease in
the BRAIN MRI is eye of the tiger sign. The
eye of the tiger is a hyperintense lesion sur-
rounded by hypointensity in the medial
aspect of bilateral globus pallidus on T2-
weighted MRI. Central hyperintensity shows
gliosis in globus pallidus and the surround-
ing hypointensity showing iron deposition
(Figures 1 and 2).15 All of the patients with
eye-of-the-tiger sign don’t have PANK2
mutation, Streckera et al. report a patient
with multiple system atrophy (MSA) and
systemic lupus erythematodes that has typi-
cal Eye of the Tiger sign in T2-weighted
MRI.16 Chaw-Liang Chang also reported a
patient with cervical dystonia that has Eye of
the Tiger without evidence of PANK2 gene
mutation.17 This sign also reported in a
patient with mitochondrial membrane pro-
tein associatedneurodegeneration (MPAN).18
The brain MRI may be normal in the Early
Stages of Classic Pantothenate Kinase
Associated Neurodegeneration and after the
progression of disease, the Eye of the Tiger
sign appear.19
Classification and presentations
It separated into classic and atypical
form. The classic form starts in early child-
hood with rapid progression of symptoms
including Parkinsonism, dystonia, cognitive
decline and dementia, dysarthria, spasticity,
seizure, optic atrophy, pigmentary retinopa-
thy that disable the patient very sever.
Atypical form of disease has later onset and
less common than classic form and it may
not be recognized by aging and has milder
symptoms with slow progression in com-
pared to classic type.20,21 The neuropsychi-
atric disorder includes Obsessive-
Compulsive Disorder (OCD) , depression
and schizophrenia-like psychosis.22 In study
that assessed the Intellectual and adaptive
behavior functioning 16 children and adults
with PKAN, there is varied cognitive
expression, also there was an inverse corre-
lation between the onset of the disease and
the cognitive impairment.23 The ophthalmo-
logic manifestation is variable and includes
saccadic pursuits, convergence impairment,
vertical hypermetric saccades, square wave
jerks and pigmentary retinopathy.24
Treatment
Medications
There is currently no suitable therapy
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for PKAN patients and different available
drugs don’t effect on disease progression.25
Dystonia can be profoundly disabling in the
affected patients and progresses over time
and involves many parts of the body. It usu-
ally treated with anticholinergics, botu-
linum toxin, Oral and Intrathecal baclofen,
benzodiazepines, Clonidine, gabapentin,
pregabalin, tetrabenazine and other anti-
spasticity drugs, alone or in combina-
tion.26,27 Vitamin B5 (pantothenate) may be
able to improve PKAN patients by increas-
ing levels of CoA and recovery of mito-
chondrial dysfunction. In mouse models of
PKAN with a high-fat ketogenic diet, this
drug was able to prevent some neurological
symptoms, But to investigate its effects,
clinical trial studies should be conducted in
the future.28-30
Surgery
Surgical procedures such as Deep brain
stimulation are now used for PKAN dis-
ease.The benefit effect of Deep brain stimu-
lation, can occur quickly after surgery, But
due to the progressive nature of the disease,
symptoms may reappear after a while and
the disease progresses again.31,32 In addition
to Deep brain stimulation, other surgical
procedures including Ablative pallidotomy
or thalmotomy can also be used, although
these surgical procedures are currently less
commonly used and replaced by Deep brain
stimulation.33 In PKAN patients that have
severe dystonia, spasticity and pain,
intrathecal baclofen (ITB) pump can allevi-
ate the symptoms.34 Blair Ford et al. shows
intrathecal baclofen is more effective if the
dystonia is associated with spasticity and
pain35 it can also use intraventricular. In a
study of Albright et al on ten patients with
severe generalized secondary and heredode-
generative dystonia, Intraventricular
baclofen was effective on dystonia.36
Iron chelation
The drugs currently used include
deferiprone, deferoxamine and
deferasirox.37 Nowadays, Deferiprone have
attracted the attention of many researchers.
It can cross the blood-brain barrier to
remove iron and prevent its accumula-
tion.38,39 In studies that investigated the
effect of deferiprone on the NBIA patients,
the use of this drug was safe and without
adverse effects. In these studies,
deferiprone reduced iron load in brain
imaging and in clinical evaluations, variable
results were obtained which requires further
investigation in the future.40,41
References
1. Hayflick SJ. Neurodegeneration with
brain iron accumulation: from genes to
pathogenesis. Semin Pediatr Neurol
2006;13:182-5.
2. Thomas M, Hayflick SJ, Jankovic J.
Clinical heterogeneity of neurodegener-
ation with brain iron accumulation and
pantothenatekinase-associated neurode-
generation. Movement Disord 2004;
19:36-42.
3. Hogarth P. Neurodegeneration with
brain iron accumulation: diagnosis and
management. J Mov Disord 2015;8:1-
13. 
4. Hayflick SJ, Westaway SK, Levinson
B, et al. Genetic, clinical, and radi-
ographic delineation of PKAN disease.
N Engl J Med 2003;348:33-40.
5. Gregory A, Polster BJ, Hayflick SJ.
Clinical and genetic delineation of neu-
rodegeneration with brain iron accumu-
lation. J Med Genet 2009;46:73-80. 
6. Pawar Y, Kalra G. A case of PKAN dis-
ease presenting as catatonic schizophre-
nia. Indian J Psychiatry 2013;55:386-9.
7. Hayflick SJ, Westaway SK,
Levinsonetal B. Genetic clinical, and
radiographic delineation of PKAN dis-
ease. New Engl J Med 2003;348:33-40.
8. Levi S, Finazzi D. Neurodegeneration
with brain iron accumulation: update on
pathogenic mechanisms. Front
Pharmacol 2014;5:99.
9. Hayflick SJ, Westaway SK, Levinson B,
                                                                                                                              Review
                                     [Neurology International 2018; 10:7516]                                                       [page 33]
Figure 1. T2 weighted Brain magnetic res-
onance imaging of the patient that shows
hyperintense lesion surrounded by
hypointensity in the medial aspect of bilat-
eral globus pallidus (eye-of-the-tiger).
Figure 2. Susceptibility weighted imaging (SWI) of the PKAN patient that shows
hypointense lesion in the medial aspect of bilateral globus pallidus. 
et al. Genetic, clinical, and radiographic
delineation of PKAN disease. N Engl J
Med 2003;348:33-40.
10. Gregory A, Westaway SK, Holm IE, et
al. Neurodegeneration associated with
genetic defects in phospholipase A(2).
Neurology 2008;71:1402-9.
11. Ching KH, Westaway SK, Gitschier J,
et al. HARP syndrome is allelic with
pantothenate kinase-associated neu-
rodegeneration. Neurology 2002;58:
1673-4.
12. Kruer MC, Boddaert N, Schneider SA,
et al. Neuroimaging features of neu-
rodegeneration with brain iron accumu-
lation. Am J Neuroradiol 2012;33:407-
14.
13. Schipper HM. Neurodegeneration with
brain iron accumulation — Clinical
syndromes and neuroimaging. Biochim
Biophys Acta 2012;1822:350-60.
14. Liman J, Wellmer A, Rostasy K, et al.
Transcranial ultrasound in  neurodegen-
eration with brain iron accumulation
(NBIA). Eur J Paediatr Neurol 2012;16:
175-8.
15. Savoiardo M, Halliday WC, Nardocci
N, et al. Hallervorden-Spatz disease:
MR and pathologic findings. Am J
Neuroradiol 1993;14:155-62.
16. Strecker K, Hesse S, Wegner F, et al.
Schneider Eye of the tiger sign in mul-
tiple system atrophy. Eur J Neurol
2007;14:e1-2.
17. Chang CL, Lin CM. Eye-of-the-Tiger
sign is not Pathognomonic of
Pantothenate Kinase-Associated
Neurodegeneration in Adult Cases.
Brain Behav 2011;1:55-6.
18. Yoganathan S, Sudhakar SV, T. Maya,
et al. Eye of tiger sign mimic in an ado-
lescent boy with mitochondrial mem-
brane protein associated neurodegener-
ation (MPAN). Brain Dev 2016;38:516-
9.
19. Chiapparini L, Savoiardo M, D’Arrigo
S, et al. The eye-of-the-tiger sign may
be absent in the early stages of classic
pantothenate kinase associated neu-
rodegeneration. Neuropediatrics
2011;42:159-62.
20. Amaral L, Gaddikeri S, Chapman PR,
et al. Neurodegeneration with brain iron
accumulation: clinicoradiological
approach to diagnosis. J Neuroimaging
2015;25:539-51.
21. Meyer E, Kurian MA, Hayflick SJ.
Neurodegeneration with brain iron
accumulation: enetic diversity and
pathophysiological mechanisms. Ann
Rev Genomics Hum Genet
2015;16:257-79.
22. Loring DW, Sethi KD, Lee GP, Meador
KJ. Neuropsychological performance in
PKAN disease : a report of two cases.
Neuropsychology 1990;4:191-9.
23. Freeman K, Gregory A, Turner A, et al.
Intellectual and adaptive behaviour
functioning in pantothenate kinase-
associated neurodegeneration. J
Intellect Disabil Res 2007;51:417-26.
24. Egan RA, Weleber RG, Hogarth P, et al.
Neuroopthamologic and electroreino-
graphic finding in pantothenate kinase
associated neurodegeneration. Am J
Ophtalmol 2005;140:167-274.
25. Schneider SA, Bhatia KP, Hardy J.
Complicated recessive dystonia
Parkinsonism syndromes. Mov Disord
2009;24:490-9.
26. Zorzi G, Zibordi F, Chiapparini L,
Nardocci N. Therapeutic Advances in
Neurodegeneration With Brain Iron
Accumulation. Semin Pediatr Neurol
2012;19:82-6.
27. Cloud LJ, Jinnah H. Treatment strate-
gies for dystonia. Exp Opin
Pharmacother 2010;11:5-15.
28. Kuo YM, Hayflick SJ, Gitschier J.
Deprivation of pantothenic acid elicits a
movement disorder and azoospermia in
a mouse model of pantothenate kinase-
associated neurodegeneration. J Inherit
Metab Dis 2007;30:310.
29. Brunetti D, Dusi S, Morbin M, et al.
Pantothenate kinase-associated neu-
rodegeneration: altered mitochondria
membrane potential and defective respi-
ration in Pank2 knock-out mouse
model. Hum Mol Genet 2012;21:5294-
305.
30. Brunetti D, Dusi S, Giordano C, et al,
Pantethine treatment is effective in
recovering the disease phenotype
induced by ketogenic diet in a pan-
tothenate kinase-associated neurode-
generation mouse model. Brain
2014;137:57-68.
31. Umemura A, Jaggi JL, Dolinskas CA, et
al. Pallidal deep brain stimulation for
longstanding severe generalized dysto-
nia in PKAN disease: case report. J
Neurosurg 2004;100:706-9.
32. Balas I, Kovacs N, Hollody K. Staged
bilateral stereotactic pallidothalamoto-
my for life-threatening dystonia in a
child with PKAN disease, Mov Disord
2006;21:82-5.
33. Justesen CR, Penn RD, Kroin JS, Egel
RT. Stereotactic pallidotomy in a child
with PKAN disease. Case report, J.
Neurosurg 1999;90:551-4.
34. Albright AL, Barry M, Fasick P, et al.
Continuous intrathecal baclofen infu-
sion for symptomatic generalized dysto-
nia [clinical studies]. Neurosurgery
1996;38:934-9.
35. Ford B, Greene P, Louis ED, et al. Use
of intrathecal baclofen in the treatment
of patients with dystonia. Arch Neurol
1996;53:1241-6.
36. Albright AL, Ferson SS.
Intraventricular baclofen for dystonia:
techniques and outcomes. Clinical arti-
cle. J Neurosurg Pediatr 2009;3:11-4.
37. Gomber S, Saxena R, Madan N.
Comparative efficacy of desferrioxam-
ine, deferiprone and in combination on
iron chelation in thalassemic children.
Indian Pediatr 2004;41: 21-7.
38. Boddaert N, Le Quan Sang KH, Rötig
A, et al. Selective iron chelation in
Friedreich ataxia: biologic and clinical
implications. Blood 2007;110: 401-8.
39. Olivieri NF, Brittenham GM, McLaren
CE, et al. Long-term safety and effec-
tiveness of iron-chelation therapy with
deferiprone for thalassemia major. New
Engl J Med 1998;339:417-23
40. Zorzi G, Zibordi F, Chiapparini L, et al.
Iron-related MRI images in patients
with Pantothenate Kinase-Associated
Neurodegeneration (PKAN) treated
with Deferiprone: results of a phase II
pilot trial. Mov Disord 2011;26:1756-9.
41. Cossu G, Abruzzese G, Matta G, et al.
Efficacy and safety of deferiprone for
the treatment of pantothenate kinase-
associated neurodegeneration (PKAN)
and neurodegeneration with brain iron
accumulation (NBIA): results from a
four years follow-up. Parkinsonism
Relat Disord 2014;20:651-4.
                             Review
[page 34]                                                        [Neurology International 2018; 10:7516]
